237 related articles for article (PubMed ID: 32168068)
1. Treatment of immune checkpoint inhibitor-induced inflammatory arthritis.
Jeurling S; Cappelli LC
Curr Opin Rheumatol; 2020 May; 32(3):315-320. PubMed ID: 32168068
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
3. [Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)].
Tingry T; Massy E; Piperno M; Auroux M; Kostine M; Maillet D; Amini-Adle M; Fabien N; Estublier C; Goncalves D; Girard N; Confavreux CB
Bull Cancer; 2021 Jun; 108(6):643-653. PubMed ID: 33902919
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer.
McCarter KR; Arabelovic S; Wang X; Wolfgang T; Yoshida K; Qian G; Kowalski EN; Vanni KMM; LeBoeuf NR; Buchbinder EI; Gedmintas L; MacFarlane LA; Rao DA; Shadick NA; Gravallese EM; Sparks JA
Semin Arthritis Rheum; 2024 Feb; 64():152335. PubMed ID: 38100899
[TBL] [Abstract][Full Text] [Related]
5. Baseline predictors of disease severity in immune checkpoint inhibitor-induced inflammatory arthritis.
Cappelli LC; Kamal O; Jones M; Bingham CO; Shah AA
Rheumatology (Oxford); 2024 May; 63(6):1518-1522. PubMed ID: 37647635
[TBL] [Abstract][Full Text] [Related]
6. Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy.
Jensen AK; Chatzidionysiou K; Torp CK; Sørensen AS; Tenstad HB; Schäfer VS; Kostine M; Jacobsen S; Leipe J; Kragstrup TW
Biomed Pharmacother; 2022 Apr; 148():112687. PubMed ID: 35228067
[TBL] [Abstract][Full Text] [Related]
7. Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis.
Roberts J; Smylie M; Walker J; Basappa NS; Chu Q; Kolinsky M; Lyddell C; Ye C
Clin Rheumatol; 2019 May; 38(5):1513-1519. PubMed ID: 30701346
[TBL] [Abstract][Full Text] [Related]
8. Rheumatologic immune checkpoint inhibitor-related adverse events.
Defoe M; Bermas BL
Curr Opin Rheumatol; 2023 May; 35(3):141-148. PubMed ID: 36912045
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.
Ladouceur A; Barnetche T; Mouterde G; Tison A; Bitoun S; Prey S; Dutriaux C; Gerard E; Pham-Ledard A; Beylot-Barry M; Zysman M; Veillon R; Domblides C; Daste A; Gross-Goupil M; Sionneau B; Lefort F; Larroquette M; Richez C; Truchetet ME; Schaeverbeke T; Kostine M
RMD Open; 2023 Nov; 9(4):. PubMed ID: 38030233
[TBL] [Abstract][Full Text] [Related]
10. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.
Cappelli LC; Brahmer JR; Forde PM; Le DT; Lipson EJ; Naidoo J; Zheng L; Bingham CO; Shah AA
Semin Arthritis Rheum; 2018 Dec; 48(3):553-557. PubMed ID: 29573850
[TBL] [Abstract][Full Text] [Related]
11. Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group.
Ghosh N; Couette N; van Binsbergen WH; Weinmann SC; Jivanelli B; Shea B; Bass AR; Benesova K; Bingham CO; Calabrese C; Cappelli LC; Chan KK; Choy E; Daoussis D; Goodman S; Hudson M; Jamal S; Leipe J; Lopez-Olivo MA; Suarez-Almazor M; van der Laken CJ; Meara AS; Liew D; Kostine M
Semin Arthritis Rheum; 2023 Feb; 58():152110. PubMed ID: 36372016
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management.
Williams SG; Mollaeian A; Katz JD; Gupta S
Expert Rev Clin Immunol; 2020 Aug; 16(8):771-785. PubMed ID: 32772596
[TBL] [Abstract][Full Text] [Related]
13. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
Belkhir R; Burel SL; Dunogeant L; Marabelle A; Hollebecque A; Besse B; Leary A; Voisin AL; Pontoizeau C; Coutte L; Pertuiset E; Mouterde G; Fain O; Lambotte O; Mariette X
Ann Rheum Dis; 2017 Oct; 76(10):1747-1750. PubMed ID: 28600350
[TBL] [Abstract][Full Text] [Related]
14. Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease-Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy.
Chan KK; Bass AR
Rheum Dis Clin North Am; 2024 May; 50(2):337-357. PubMed ID: 38670731
[TBL] [Abstract][Full Text] [Related]
15. Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients.
Richter MD; Crowson C; Kottschade LA; Finnes HD; Markovic SN; Thanarajasingam U
Arthritis Rheumatol; 2019 Mar; 71(3):468-475. PubMed ID: 30281202
[TBL] [Abstract][Full Text] [Related]
16. Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis.
Subedi A; Williams SG; Yao L; Maharjan S; Strauss J; Sharon E; Thomas A; Apolo AB; Gourh P; Hasni SA; Gulley JL; Kaplan MJ; Katz JD; Gupta S
JAMA Netw Open; 2020 Feb; 3(2):e200032. PubMed ID: 32101306
[TBL] [Abstract][Full Text] [Related]
17. Arthritis risk with immune checkpoint inhibitor therapy for cancer.
Pundole X; Abdel-Wahab N; Suarez-Almazor ME
Curr Opin Rheumatol; 2019 May; 31(3):293-299. PubMed ID: 30870217
[TBL] [Abstract][Full Text] [Related]
18. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.
Mooradian MJ; Nasrallah M; Gainor JF; Reynolds KL; Cohen JV; Lawrence DP; Miloslavsky EM; Kohler MJ; Sullivan RJ; Schoenfeld SR
Semin Arthritis Rheum; 2019 Jun; 48(6):1127-1132. PubMed ID: 30409415
[TBL] [Abstract][Full Text] [Related]
19. Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis.
Efuni E; Cytryn S; Boland P; Niewold TB; Pavlick A; Weber J; Sandigursky S
J Clin Rheumatol; 2021 Oct; 27(7):267-271. PubMed ID: 31977647
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor-induced musculoskeletal manifestations.
Angelopoulou F; Bogdanos D; Dimitroulas T; Sakkas L; Daoussis D
Rheumatol Int; 2021 Jan; 41(1):33-42. PubMed ID: 32743706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
